NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer (NK) cell-based immunotherapies targeting oncology and neurodegenerative diseases, including Alzheimer's. The company entered public markets through its de-SPAC merger with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Industrial Corp. that completed its initial public offering in 2021. On January 31, 2022, NKGen filed a Form 10-Q/A, amending a previously submitted quarterly report as part of its public disclosure obligations during the pre-close period. The company operates in the biotechnology and cell therapy sector, advancing its proprietary SNK platform in clinical development. Sign up at SpacDesk for full filing history, deal analytics, and comprehensive SPAC data on NKGen Biotech and thousands of other transactions.